Home/Pipeline/OmniCAR

OmniCAR

Universal CAR‑T platform

PreclinicalActive

Key Facts

Indication
Universal CAR‑T platform
Phase
Preclinical
Status
Active
Company

About Prescient Therapeutics

Australian early‑stage oncology biotech leveraging a GGT‑1 inhibitor and novel CAR‑T platforms to address unmet‑need cancers.

View full company profile

Therapeutic Areas